Abhishek Kumar Verma1* , Zaharaddeen Umar Na’abba1, Najib Lawan Yahaya1, Mudassir Alam2, Mudassir Lawal1, Binta Sunusi Shuaibu1, Umar Adamu Hamza1, Usman Rabi'u Bello1, Abubakar Dabo Dalhat1 and Mayadhar Barik1*
1Department of Life Sciences, Mewar University, Gangrar, Chittorgarh, Rajasthan, India
2Department of Zoology, Aligarh Muslim University, Aligarh, Uttar Pradesh, India
*Corresponding Author: Abhishek Kumar Verma, Assistant Professor, Department of Life Sciences, Mewar University, Gangrar, Chittorgarh, Rajasthan, India.
Received: July 15, 2020; Published: December 30, 2020
Severe acute respiratory syndrome 2 (SARS-CoV- 2) is a novel coronavirus that causes coronavirus disease 2019 (COVID-19), an infection characterized by flu-like symptoms, progressing in some cases to acute respiratory distress syndrome (ARDS). That WHO to declare it as global pandemic. Based on the information gained from the responses to other RNA coronaviruses, including the strains that cause severe acute respiratory syndrome (SARS)-coronaviruses and Middle East respiratory syndrome (MERS), effort are put in place to develop effective therapeutic agent against the COVID-19. Currently, there is no therapeutic candidate for this virus but the United States Food and Drug Administration (FDA) has provided emergency authorization for the use of chloroquine and hydroxychloroquine and other promising antiviral drugs. Although the result of ongoing clinical trials are not out, but some provide promising result in vitro. The most important factor associated with pathophysiology of SARS-CoV-2 is the host immune response which results due to binding of spike glycoprotein to its receptor angiotensin-converting enzyme 2 (ACE2) but concerned has arose for the continuous expressing of ACE in affected patient especially patient with pregnancy as this might increase the susceptibility of the patient although there is no strong evidence for it involvement for susceptibility of the affected patients. Despite the continuous evolving and dynamics on the literature of COVID-19, using the existing knowledge, possible drug target have been identified for the development of the effective vaccine. Since there is no effective therapeutic drug for the current pandemic, drug repurposing might be a viable strategy and specific prophylaxis regimen should be provide to reduce the toxicity on the affected patients and the clinical trial should be based on the specificity and efficacy of the drug. This review provide information on the Novel invention and new guidelines or protocol for SARS-COV-2.
Keywords: Immunological; Pharmacological; Theraputics Targets; Recent Advancements; SARS-CoV-2
Citation: Abhishek Kumar Verma, Mayadhar Barik., et al. “Immunological, Pharmacological, Pharmacokinetics, Therapeutic Targets and Various Therapy for SARS-CoV-2: Recent Advancement and Future Prospective". Acta Scientific Pharmaceutical Sciences 5.1 (2020): 110-143.
Copyright: © 2020 Abhishek Kumar Verma, Mayadhar Barik., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.